Drug Profile
Alirocumab - Regeneron/Sanofi
Alternative Names: Anti-PCSK9 monoclonal antibody - Regeneron/Sanofi; Anti-proprotein convertase subtilisin kexin type 9 monoclonal antibody - Regeneron/Sanofi; Praluent; REGN-727; SAR-236553Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Regeneron Pharmaceuticals; Sanofi
- Class Antihyperlipidaemics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Coronary disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipoproteinaemia type II
Most Recent Events
- 20 Mar 2024 Registered for Hyperlipoproteinaemia type II (In adolescents, In children) in Liechtenstein, Norway, Iceland, European Union (SC) prior to March 2024
- 11 Mar 2024 Launched for Hyperlipoproteinaemia type II (In adolescents, In children) in USA (SC)
- 11 Mar 2024 Regeneron Pharmaceuticals with Sanofi announces intention to submit regulatory application for Hyperlipoproteinaemia type II (In children) by mid 2023